Alamar Biosciences, Inc. (ALMR) News
Follow Alamar Biosciences, Inc. (ALMR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ALMR Reports Fiscal Q3 Loss
Attributable profit was -4787万美元, down 111.02% year over year; basic EPS was -1.02美元.
EQUITY | Nov 04, 2026, 10:58 AM UTC
M
Alamar Biosciences Raises 2026 Revenue Guidance to $121M–$123M
The company’s full-year 2026 revenue outlook is above the FactSet consensus estimate of $118.6 million.
EARNINGS | Nov 03, 2026, 11:03 PM UTC
M
Alamar Biosciences Reports Quarterly Results Through September 30
Alamar Biosciences reported results for the quarter ended September 30; no figures were provided.
EQUITY | Nov 03, 2026, 10:56 PM UTC
M
Alamar Biosciences Q3 Net Loss Widens 66% to $13.3 Million
Q3 2026 revenue rose 68% year over year to $33.5 million.
EQUITY | Nov 03, 2026, 10:38 PM UTC
M
Alamar Biosciences Expects 2026 Revenue of $121M-$123M
Alamar Biosciences expects 2026 revenue of $121 million to $123 million; FactSet estimates $118.6 million.
EARNINGS | Nov 03, 2026, 10:17 PM UTC
M
Alamar Biosciences Reports Q3 2026 Results, Raises Revenue Guidance
Alamar Biosciences reported results for the quarter ended September 30, 2026, and raised its 2026 revenue guidance.
EQUITY | Nov 03, 2026, 09:14 PM UTC
M
Alamar Biosciences (ALMR) to Report Third-Quarter 2026 Results on Nov. 3
EQUITY | Oct 08, 2026, 08:05 PM UTC
L
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemabFREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. NASDAQ:AL
NEWS | Sep 24, 2026, 10:53 PM UTC
L
Alamar Biosciences to participate in Morgan Stanley Global Healthcare Conference
Alamar Biosciences said it will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
ALMR - Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
ALMR - Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Sep 01, 2026, 08:06 PM UTC
L
Alamar Biosciences appoints Robert Ragusa to board
Alamar Biosciences named Robert Ragusa a Class I director effective September 1, 2026, and added him to its audit, compensation and nominating and corporate governance committees.
REGULATION | Sep 01, 2026, 08:04 PM UTC
L
Crinetics, Alamar, Halozyme Report Earnings
Crinetics, Alamar, and Halozyme report better-than-expected Q2 financial results
EARNINGS | Aug 12, 2026, 12:58 PM UTC
L
Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32
Stifel analyst Daniel Arias maintains Alamar Biosciences (NASDAQ: ALMR ) with a Buy and raises the price target from $28 to $32.
EQUITY | Aug 11, 2026, 05:41 PM UTC
L
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences Inc. (NASDAQ: ALMR ) shares are trading higher on Tuesday as the company is expanding its global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The proteomics company is e
EARNINGS | Aug 11, 2026, 05:25 PM UTC